[go: up one dir, main page]

PE20020424A1 - Procedimiento para la preparacion de formulaciones en polvo - Google Patents

Procedimiento para la preparacion de formulaciones en polvo

Info

Publication number
PE20020424A1
PE20020424A1 PE2001001002A PE2001001002A PE20020424A1 PE 20020424 A1 PE20020424 A1 PE 20020424A1 PE 2001001002 A PE2001001002 A PE 2001001002A PE 2001001002 A PE2001001002 A PE 2001001002A PE 20020424 A1 PE20020424 A1 PE 20020424A1
Authority
PE
Peru
Prior art keywords
particle size
active principle
substance
procedure
preparation
Prior art date
Application number
PE2001001002A
Other languages
English (en)
Inventor
Michael Walz
Georg Boeck
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26007343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20020424(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2001138022 external-priority patent/DE10138022A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20020424A1 publication Critical patent/PE20020424A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE FORMULACIONES EN POLVOS DE INHALACION, CARACTERIZADO PORQUE N+m PORCIONES DE APROXIMADAMENTE IGUAL TAMANO DE SUSTANCIA CON UNA DISTRIBUCION MAYOR DEL TAMANO DE PARTICULAS (COADYUVANTE) Y N PORCIONES DE IGUAL TAMANO DE UNA SUSTANCIA CON UNA DISTRIBUCION MENOR DEL TAMANO DE PARTICULAS (PRINCIPIO ACTIVO) SE ANADEN DE FORMA INTERMITENTE EN CAPAS POR MEDIO DE UN DISPOSITIVO DE TAMIZADO ADECUADO A UN RECIPIENTE DE MEZCLA Y, DESPUES DE LA ADICION COMPLETA , LAS 2N+m CAPAS DE LOS DOS COMPONENTES SE MEZCLAN EFECTUANDOSE PRIMERAMENTE LA ADICION DE UNA PORCION DE LA SUSTANCIA CON UN TAMANO DE PARTICULAS MAYOR SIENDO N UN NUMERO ENTERO MAYOR QUE 0 PREFERIBLEMENTE MAYOR QUE 5 Y m ES 0-1. SE OBTIENEN POLVOS DE INHALACION QUE CONTIENEN MENOS DE 5% DE PREFERENCIA 2% DEL PRINCIPIO ACTIVO. EL PRINCIPIO ACTIVO PRESENTA UN TAMANO DE PARTICULAS DE 0,5um A 10 um, EL COADYUVANTE UTILIZADO TIENE UN TAMANO MEDIO DE 10 A 100um. EL PRINCIPIO ACTIVO SE SELECCIONADA DE COMPUESTOS BETAMIMETICOS, ANTICOLINERGICOS, CORTICOSTEROIDES Y AGONISTAS DE DOPAMINA
PE2001001002A 2000-10-12 2001-10-10 Procedimiento para la preparacion de formulaciones en polvo PE20020424A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10050635 2000-10-12
DE2001138022 DE10138022A1 (de) 2001-08-10 2001-08-10 Verfahren zur Herstellung von Pulverformulierungen

Publications (1)

Publication Number Publication Date
PE20020424A1 true PE20020424A1 (es) 2002-07-02

Family

ID=26007343

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001002A PE20020424A1 (es) 2000-10-12 2001-10-10 Procedimiento para la preparacion de formulaciones en polvo

Country Status (40)

Country Link
US (2) US6585959B2 (es)
EP (1) EP1326585B2 (es)
JP (2) JP4986369B2 (es)
KR (1) KR100849837B1 (es)
CN (1) CN1269470C (es)
AR (1) AR034166A1 (es)
AT (1) ATE319422T1 (es)
AU (2) AU2002218220B2 (es)
BG (1) BG66194B1 (es)
BR (1) BR0114316A (es)
CA (1) CA2425005C (es)
CY (1) CY1105037T1 (es)
CZ (1) CZ300022B6 (es)
DE (1) DE50109178D1 (es)
DK (1) DK1326585T4 (es)
EA (1) EA004689B1 (es)
EE (1) EE05146B1 (es)
EG (1) EG24478A (es)
ES (1) ES2259046T5 (es)
HK (1) HK1060522A1 (es)
HR (1) HRP20030277B1 (es)
HU (1) HU229512B1 (es)
IL (2) IL154919A0 (es)
ME (1) ME02762B (es)
MX (1) MXPA03003219A (es)
MY (1) MY155912A (es)
NO (1) NO333719B1 (es)
NZ (1) NZ525781A (es)
PE (1) PE20020424A1 (es)
PL (1) PL204733B1 (es)
PT (1) PT1326585E (es)
RS (1) RS50495B (es)
SA (1) SA01220518B1 (es)
SI (1) SI1326585T2 (es)
SK (1) SK285841B6 (es)
TW (1) TWI283180B (es)
UA (1) UA75375C2 (es)
UY (1) UY26960A1 (es)
WO (1) WO2002030390A2 (es)
ZA (1) ZA200301349B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE275391T1 (de) * 2000-10-12 2004-09-15 Boehringer Ingelheim Pharma Neue tiotropium-haltige inhalationspulver
US6443152B1 (en) * 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
EP1397134A2 (en) * 2001-05-25 2004-03-17 Boehringer Ingelheim Pharma GmbH & Co.KG Combination of a dopamine d2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US20030008001A1 (en) * 2001-06-13 2003-01-09 Boehringer Ingelheim Pharma Kg Process for cleaning hard gelatine capsules
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10141377A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
DE10141376A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
US7309707B2 (en) * 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244415B2 (en) * 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
WO2003084509A1 (en) * 2002-04-04 2003-10-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulations suitable for inhalation
NZ538965A (en) * 2002-08-21 2006-11-30 Norton Healthcare Ltd Dry powder inhalation compositions
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
GB0219513D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions including coarse carrier
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10351663A1 (de) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
DE10317461A1 (de) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7462367B2 (en) 2003-07-11 2008-12-09 Boehringer Ingelheim International Gmbh Anticholinergic powder formulations for inhalation
DE10331350A1 (de) * 2003-07-11 2005-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation enthaltend ein neues Anticholinergikum
PT1699434E (pt) 2003-09-02 2011-05-03 Norton Healthcare Ltd Processo para a prepara??o de um medicamento
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US8686148B2 (en) 2003-11-03 2014-04-01 Boehringer Ingelheim International Gmbh Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
CN102964344B (zh) 2003-11-03 2014-12-31 贝林格尔.英格海姆国际有限公司 噻托铵盐、其医药制剂及其用途
AU2004294890B2 (en) * 2003-12-03 2010-08-26 Boehringer Ingelheim International Gmbh Pre-metered dry powder inhaler for moisture-sensitive medicaments
DE102004048389A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
CN101155590A (zh) 2005-02-10 2008-04-02 葛兰素集团有限公司 使用预分选技术制备乳糖的方法以及由此形成的药物制剂
GB0507835D0 (en) * 2005-04-18 2005-05-25 Solexa Ltd Method and device for nucleic acid sequencing using a planar wave guide
ES2393794T3 (es) 2005-05-02 2012-12-28 Boehringer Ingelheim International Gmbh Nuevas formas cristalinas de bromuro de tiotropio
DE102005059602A1 (de) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
ES2569359T3 (es) 2007-07-06 2016-05-10 Vectura Delivery Devices Limited Inhalador
EP2264042B1 (en) * 2007-07-27 2012-07-18 Cargill, Incorporated Micronization of polyols
EP2082766A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Blister Strip Coil Forming
EP2082768A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082767A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082771A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082772A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
EP2662046B1 (en) 2008-05-09 2023-03-15 Nuvaira, Inc. Systems and assemblies for treating a bronchial tree
CN103145766B (zh) * 2008-07-24 2015-02-11 乔治洛德方法研究和开发液化空气有限公司 用于沉积含过渡金属的膜的杂配型环戊二烯基过渡金属前体
TWI491416B (zh) 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
AU2010315396B2 (en) 2009-10-27 2016-05-05 Nuvaira, Inc Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
CA2780608C (en) 2009-11-11 2019-02-26 Innovative Pulmonary Solutions, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
EP2575786B1 (en) 2010-06-03 2017-11-15 Sima Patent ve Lisanslama Hizmetleri Ltd.Sti. Process for dry powder formulations
TR201007251A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Kalsiyum kanal blokörü formülasyonu.
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
WO2016005443A1 (en) 2014-07-09 2016-01-14 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of formulations for inhalation
PT3175842T (pt) * 2015-12-03 2020-03-04 Tiefenbacher Alfred E Gmbh & Co Kg Processo de mistura de pó seco
WO2020013793A2 (en) * 2018-07-12 2020-01-16 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising dopamine agonists
WO2022146255A1 (en) * 2020-12-31 2022-07-07 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860618A (en) 1967-08-08 1975-01-14 Philip Saxton Hartley Chromone
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
US3957965A (en) 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
BE891013A (fr) 1980-11-05 1982-05-05 Fisons Ltd Compositions pharmaceutique
JPS60150823A (ja) * 1984-01-17 1985-08-08 Satake Eng Co Ltd 穀物混合装置
JPH0439388A (ja) * 1990-06-04 1992-02-10 Teijin Ltd 土砂と繊維状物との混合方法
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
JPH06198156A (ja) * 1993-01-06 1994-07-19 Nagasaki Pref Gov 噴霧積層混合器
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
US6645466B1 (en) * 1998-11-13 2003-11-11 Jago Research Ag Dry powder for inhalation
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1326585A2 (de) 2003-07-16
IL154919A0 (en) 2003-10-31
HRP20030277B1 (en) 2011-09-30
SI1326585T1 (sl) 2006-06-30
AU1822002A (en) 2002-04-22
EA004689B1 (ru) 2004-06-24
JP2004510806A (ja) 2004-04-08
AR034166A1 (es) 2004-02-04
HUP0301268A2 (hu) 2003-10-28
MXPA03003219A (es) 2004-12-03
EP1326585B2 (de) 2010-09-29
UA75375C2 (en) 2006-04-17
US6585959B2 (en) 2003-07-01
YU27403A (sh) 2006-03-03
US20020106332A1 (en) 2002-08-08
CA2425005A1 (en) 2003-04-04
BR0114316A (pt) 2003-08-26
CZ300022B6 (cs) 2009-01-14
BG66194B1 (bg) 2012-01-31
DK1326585T4 (da) 2011-01-10
SI1326585T2 (sl) 2011-01-31
ATE319422T1 (de) 2006-03-15
EE05146B1 (et) 2009-04-15
ES2259046T3 (es) 2006-09-16
MEP42708A (en) 2011-02-10
BG107673A (bg) 2003-11-28
SA01220518B1 (ar) 2006-12-10
ZA200301349B (en) 2004-06-30
ME02762B (me) 2011-05-10
JP2009197025A (ja) 2009-09-03
SK4372003A3 (en) 2003-07-01
NO20031692L (no) 2003-06-06
HU229512B1 (en) 2014-01-28
EE200300170A (et) 2003-06-16
HRP20030277A2 (en) 2005-02-28
AU2002218220B2 (en) 2006-06-15
CA2425005C (en) 2008-08-05
PL362511A1 (en) 2004-11-02
TWI283180B (en) 2007-07-01
KR20030051706A (ko) 2003-06-25
DK1326585T3 (da) 2006-05-22
MY155912A (en) 2015-12-15
EP1326585B1 (de) 2006-03-08
HK1060522A1 (en) 2004-08-13
EG24478A (en) 2009-08-03
CY1105037T1 (el) 2010-03-03
CN1469733A (zh) 2004-01-21
NO333719B1 (no) 2013-09-02
WO2002030390A2 (de) 2002-04-18
RS50495B (sr) 2010-03-02
WO2002030390A3 (de) 2002-06-27
DE50109178D1 (de) 2006-05-04
NO20031692D0 (no) 2003-04-11
JP4986369B2 (ja) 2012-07-25
PT1326585E (pt) 2006-05-31
KR100849837B1 (ko) 2008-08-01
CN1269470C (zh) 2006-08-16
IL154919A (en) 2011-01-31
HUP0301268A3 (en) 2005-05-30
NZ525781A (en) 2004-11-26
UY26960A1 (es) 2002-06-20
EA200300429A1 (ru) 2003-10-30
ES2259046T5 (es) 2011-02-28
SK285841B6 (sk) 2007-09-06
USRE38912E1 (en) 2005-12-06
PL204733B1 (pl) 2010-02-26

Similar Documents

Publication Publication Date Title
PE20020424A1 (es) Procedimiento para la preparacion de formulaciones en polvo
HRP20141086T1 (hr) Pesticidni pripravak poboljšane uäśinkovitosti i postupak poboljšanja uäśinkovitosti pesticidnih djelatnih tvari
ES2194480T3 (es) Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
DK0587744T3 (da) Tygbar sammensætning til frigørelse af et lægemiddel
EP2286793A3 (en) Pharmaceutical formulations comprising cannabidiol
ECSP10010184A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea
CL2015001960A1 (es) (divisional solicitud 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
NZ606194A (en) Isoxazoline derivatives as antiparasitic agents
FI964634A0 (fi) Flutikasonipropionaattiformuloita
AR025937A1 (es) Composicion farmaceutica que comprende un antigeno, un inmunoestimulante y un adyuvante policationico.
DE69936515D1 (de) Aerosolformulierungen von salmeterol xinafoate
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
CO5280133A1 (es) Dispositivo y sistema para aerosolizar formulaciones farmaceuticas
AUPQ573300A0 (en) Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
AR007827A1 (es) 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos.
ATE315930T1 (de) Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform
CR7500A (es) Formas de dosificacion de azitromicida con efectos secundarios reducidos
BR0110141A (pt) Melhorias em ou relacionando-se a formulações para uso em dispositivos inaladores
AR065970A2 (es) Una composicion farmaceutica oral solida que comprende una combinacion de metformin y glibenclamida y uso de dicha composicion
CO4130180A1 (es) Composiciones para el cuidado de la piel que contienen una emulsion de agua en aceite y un retinoide
ES2177289T3 (es) Producto sanitario adhesivo.
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
DK1531800T3 (da) Stealth-lipidnanokapsler, fremgangsmåder til fremstilling deraf som en bærer for aktivt princip(per)
AR034898A1 (es) Composicion cristalina que contiene escitalopram

Legal Events

Date Code Title Description
FG Grant, registration